Cargando…

Prognostic Significance of Blood-Based Baseline Biomarkers in Treatment-Resistant Depression: A Literature Review of Available Studies on Treatment Response

Major depressive disorder is a leading cause of disability worldwide and a major contributor to the overall global burden of disease. While there are several options for antidepressant treatment, only about 40–60% of patients respond to initial monotherapy, while 30–40% of patients may even show res...

Descripción completa

Detalles Bibliográficos
Autores principales: Gkesoglou, Theano, Bargiota, Stavroula I., Iordanidou, Eleni, Vasiliadis, Miltiadis, Bozikas, Vasilios-Panteleimon, Agorastos, Agorastos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317233/
https://www.ncbi.nlm.nih.gov/pubmed/35884746
http://dx.doi.org/10.3390/brainsci12070940
_version_ 1784755005587193856
author Gkesoglou, Theano
Bargiota, Stavroula I.
Iordanidou, Eleni
Vasiliadis, Miltiadis
Bozikas, Vasilios-Panteleimon
Agorastos, Agorastos
author_facet Gkesoglou, Theano
Bargiota, Stavroula I.
Iordanidou, Eleni
Vasiliadis, Miltiadis
Bozikas, Vasilios-Panteleimon
Agorastos, Agorastos
author_sort Gkesoglou, Theano
collection PubMed
description Major depressive disorder is a leading cause of disability worldwide and a major contributor to the overall global burden of disease. While there are several options for antidepressant treatment, only about 40–60% of patients respond to initial monotherapy, while 30–40% of patients may even show resistance to treatment. This article offers a narrative review of those studies evaluating the predictive properties of various blood-based baseline biomarkers regarding treatment responses to the pharmacological, stimulation, or behavioral treatment of patients with treatment-resistant depression (TRD). Our results show that overall, there is only a very limited number of studies assessing baseline peripheral biomarkers regarding treatment response in TRD. Although there is some evidence for the predictive significance of particular biomarkers (e.g., IL-6, CRP, BDNF), the majority of the results are either single-study reports or studies with conflicting results. This may contribute to the wide variety of treatment protocols and different TRD definition criteria, the small number of patients included, and the existence of different biological phenotypes of the disorder used within the various studies. Taken together, there does not yet appear to be any specific baseline peripheral biomarker with sufficient discriminative predictive validity that can be used in the routine clinical practice of TRD. The discovery of new biomarkers and the better clinical characterization of known biomarkers could support the better classification and staging of TRD, the development of personalized treatment algorithms with higher rates of remission and fewer side effects, and the development of new precision drugs for specific subgroups of patients.
format Online
Article
Text
id pubmed-9317233
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93172332022-07-27 Prognostic Significance of Blood-Based Baseline Biomarkers in Treatment-Resistant Depression: A Literature Review of Available Studies on Treatment Response Gkesoglou, Theano Bargiota, Stavroula I. Iordanidou, Eleni Vasiliadis, Miltiadis Bozikas, Vasilios-Panteleimon Agorastos, Agorastos Brain Sci Review Major depressive disorder is a leading cause of disability worldwide and a major contributor to the overall global burden of disease. While there are several options for antidepressant treatment, only about 40–60% of patients respond to initial monotherapy, while 30–40% of patients may even show resistance to treatment. This article offers a narrative review of those studies evaluating the predictive properties of various blood-based baseline biomarkers regarding treatment responses to the pharmacological, stimulation, or behavioral treatment of patients with treatment-resistant depression (TRD). Our results show that overall, there is only a very limited number of studies assessing baseline peripheral biomarkers regarding treatment response in TRD. Although there is some evidence for the predictive significance of particular biomarkers (e.g., IL-6, CRP, BDNF), the majority of the results are either single-study reports or studies with conflicting results. This may contribute to the wide variety of treatment protocols and different TRD definition criteria, the small number of patients included, and the existence of different biological phenotypes of the disorder used within the various studies. Taken together, there does not yet appear to be any specific baseline peripheral biomarker with sufficient discriminative predictive validity that can be used in the routine clinical practice of TRD. The discovery of new biomarkers and the better clinical characterization of known biomarkers could support the better classification and staging of TRD, the development of personalized treatment algorithms with higher rates of remission and fewer side effects, and the development of new precision drugs for specific subgroups of patients. MDPI 2022-07-18 /pmc/articles/PMC9317233/ /pubmed/35884746 http://dx.doi.org/10.3390/brainsci12070940 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gkesoglou, Theano
Bargiota, Stavroula I.
Iordanidou, Eleni
Vasiliadis, Miltiadis
Bozikas, Vasilios-Panteleimon
Agorastos, Agorastos
Prognostic Significance of Blood-Based Baseline Biomarkers in Treatment-Resistant Depression: A Literature Review of Available Studies on Treatment Response
title Prognostic Significance of Blood-Based Baseline Biomarkers in Treatment-Resistant Depression: A Literature Review of Available Studies on Treatment Response
title_full Prognostic Significance of Blood-Based Baseline Biomarkers in Treatment-Resistant Depression: A Literature Review of Available Studies on Treatment Response
title_fullStr Prognostic Significance of Blood-Based Baseline Biomarkers in Treatment-Resistant Depression: A Literature Review of Available Studies on Treatment Response
title_full_unstemmed Prognostic Significance of Blood-Based Baseline Biomarkers in Treatment-Resistant Depression: A Literature Review of Available Studies on Treatment Response
title_short Prognostic Significance of Blood-Based Baseline Biomarkers in Treatment-Resistant Depression: A Literature Review of Available Studies on Treatment Response
title_sort prognostic significance of blood-based baseline biomarkers in treatment-resistant depression: a literature review of available studies on treatment response
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317233/
https://www.ncbi.nlm.nih.gov/pubmed/35884746
http://dx.doi.org/10.3390/brainsci12070940
work_keys_str_mv AT gkesogloutheano prognosticsignificanceofbloodbasedbaselinebiomarkersintreatmentresistantdepressionaliteraturereviewofavailablestudiesontreatmentresponse
AT bargiotastavroulai prognosticsignificanceofbloodbasedbaselinebiomarkersintreatmentresistantdepressionaliteraturereviewofavailablestudiesontreatmentresponse
AT iordanidoueleni prognosticsignificanceofbloodbasedbaselinebiomarkersintreatmentresistantdepressionaliteraturereviewofavailablestudiesontreatmentresponse
AT vasiliadismiltiadis prognosticsignificanceofbloodbasedbaselinebiomarkersintreatmentresistantdepressionaliteraturereviewofavailablestudiesontreatmentresponse
AT bozikasvasiliospanteleimon prognosticsignificanceofbloodbasedbaselinebiomarkersintreatmentresistantdepressionaliteraturereviewofavailablestudiesontreatmentresponse
AT agorastosagorastos prognosticsignificanceofbloodbasedbaselinebiomarkersintreatmentresistantdepressionaliteraturereviewofavailablestudiesontreatmentresponse